During a talk at the Jefferies Healthcare Services Conference this week, CFO Sam Samad said the business has exceeded the company's expectations.

Quest Diagnostics will soon begin offering a new blood-based in-vitro diagnostic test for Alzheimer’s. The disease affects nearly 7 million Americans. The Lumipulse G pTau 217/β-Amyloid 1-42 Plasma ...

Test to be available for clinical and research use as soon as this summer, building on Quest's pioneering blood-based AD-Detect™ product line for assessing symptomatic patients SECAUCUS, N.J., July 9, ...

Quest Diagnostics unveiled a first-to-market blood test available for consumer purchase that helps assess the potential risk of developing Alzheimer’s disease. In adding AD-Detect, a single-blood-draw ...

Guardant Health and Quest Diagnostics will collaborate to offer Guardant’s Shield blood-based colorectal cancer test through ...

Narrow-moat Quest Diagnostics DGX delivered second-quarter results that slightly exceeded our expectations on the top line, but that was offset by earnings that fell slightly short of our full-year ...

(RTTNews) - Quest Diagnostics Incorporated (DGX), a provider of diagnostic information services, Tuesday said it partnered with The University of Texas MD Anderson Cancer Center to develop a ...